

ASX Announcement

NHMRC \$768,000 grant for development of AD-114 in Chronic Kidney Disease

MELBOURNE Australia, 7 December, 2017: AdAlta Limited (ASX:1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to announce that Professor Carol Pollock from the University of Sydney has been awarded a project grant totalling \$768,000 from the National Health and Medical Research Council (NHMRC) to evaluate its lead therapeutic, AD-114 for the treatment of Chronic Kidney Disease (CKD).

The project grant, titled “A novel and unique protein i-body for the treatment of Chronic Kidney Disease through targeting CXCR4” will begin on 1 January 2018 and run over four years. The grant will provide non-dilutive funding to build on the initial work completed by the Kolling Institute and University of Sydney that demonstrated the anti-fibrotic effects of AD-114 in the kidney via a different mechanism of action from currently-approved therapies.

AD-114 has the potential to provide a novel treatment for CKD which currently affects an estimated 1.7 million Australians.

AD-114 differs from existing treatment options and others currently in clinical development as it binds to the chemokine receptor CXCR4. The target CXCR4 is expressed at low levels or absent in healthy tissue and is increased and at high levels in tissue affected by a number of disease states, including fibrosis. AD-114 is the only anti-CXCR4 drug candidate being developed for the treatment of fibrosis.

AdAlta’s CEO, Sam Cobb said, “The research collaboration with the Kolling Institute and University of Sydney has provided the opportunity to expand the AD-114 pre-clinical package; demonstrating anti-fibrotic effects across a range of fibrotic diseases, which will be important to potential pharmaceutical partners. We are looking forward to further developing AD-114 for Chronic Kidney Disease, providing an additional clinical application which further enhances the value of AD-114.”

Professor Carol Pollock added “An increase in diabetes and obesity across the world is leading to a massive surge in the number of people diagnosed with CKD. The medical community is looking for alternate treatment options to treat CKD, highlighting the importance of research funding to evaluate new clinical targets. We are excited by the opportunity to further evaluate CXCR4’s involvement and this novel i-body for the treatment of Chronic Kidney Disease”.

Notes to Editors

About AdAlta

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: www.adalta.com.au.

For more information, please contact:

AdAlta Limited

Sam Cobb, CEO

Tel: +61 (0)3 9479 5159

E: s.cobb@adalta.com.au